Zhu Liqiong, Zhao Zongxing, Liu Ao, Wang Xin, Geng Xiaotao, Nie Yu, Zhao Fen, Li Minghuan
Department of Clinical Medicine, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Front Oncol. 2022 Sep 13;12:774816. doi: 10.3389/fonc.2022.774816. eCollection 2022.
Clinical T4 stage (cT4) esophageal tumors are difficult to be surgically resected, and definitive radiotherapy (RT) or chemoradiotherapy (dCRT) remains the main treatment. The study aims to analyze the association between the status of lymph node (LN) metastasis and survival outcomes in the cT4 stage esophageal squamous cell carcinoma (ESCC) patients that underwent treatment with dCRT or RT.
This retrospective study analyzed the clinical data of 555 ESCC patients treated with dCRT or RT at the Shandong Cancer Hospital and the Liaocheng People's Hospital from 2010 to 2017. Kaplan-Meier and Cox regression analyses was performed to determine the relationship between LN metastasis and survival outcomes of cT4 and non-cT4 ESCC patients. The chi-square test was used to evaluate the differences in the local and distal recurrence patterns in the ESCC patients belonging to various clinical T stages.
The 3-year survival rates for patients with non-cT4 ESCC and cT4 ESCC were 47.9% and 30.8%, respectively. The overall survival (OS) and progression-free survival (PFS) rates were strongly associated with the status of LN metastasis in the entire cohort (all < 0.001) and the non-cT4 group (all < 0.001) but not in the cT4 group. The local recurrence rates were 60.7% for the cT4 ESCC patients and 45.1% for the non-cT4 ESCC patients ( < 0.001). Multivariate analysis showed that clinical N stage ( = 0.002), LN size ( = 0.007), and abdominal LN involvement ( = 0.011) were independent predictors of favorable OS in the non-cT4 group. However, clinical N stage ( = 0.824), LN size ( = 0.383), and abdominal LN involvement ( = 0.337) did not show any significant correlation with OS in the cT4 ESCC patients.
Our data demonstrated that the status of LN metastasis did not correlate with OS in the cT4 ESCC patients that received dCRT or RT. Furthermore, the prevalence of local recurrence was higher in the cT4 ESCC patients.
临床T4期(cT4)食管肿瘤难以进行手术切除,确定性放疗(RT)或放化疗(dCRT)仍是主要治疗方法。本研究旨在分析接受dCRT或RT治疗的cT4期食管鳞状细胞癌(ESCC)患者的淋巴结(LN)转移状态与生存结局之间的关联。
这项回顾性研究分析了2010年至2017年在山东省肿瘤医院和聊城市人民医院接受dCRT或RT治疗的555例ESCC患者的临床资料。采用Kaplan-Meier法和Cox回归分析来确定cT4和非cT4期ESCC患者的LN转移与生存结局之间的关系。采用卡方检验评估不同临床T分期的ESCC患者局部和远处复发模式的差异。
非cT4期ESCC患者和cT4期ESCC患者的3年生存率分别为47.9%和30.8%。在整个队列(均P<0.001)和非cT4组(均P<0.001)中,总生存(OS)和无进展生存(PFS)率与LN转移状态密切相关,但在cT4组中并非如此。cT4期ESCC患者的局部复发率为60.7%,非cT4期ESCC患者为45.1%(P<0.001)。多因素分析显示,临床N分期(P=0.002)、LN大小(P=0.007)和腹部LN受累情况(P=0.011)是非cT4组OS良好的独立预测因素。然而,临床N分期(P=0.824)、LN大小(P=0.383)和腹部LN受累情况(P=0.337)在cT4期ESCC患者中与OS均无显著相关性。
我们的数据表明,接受dCRT或RT治疗的cT4期ESCC患者的LN转移状态与OS无关。此外,cT4期ESCC患者的局部复发率更高。